2.14

0.47% -0.010

Erasca Inc (ERAS)

Overview News Price History Option Chain Financials Why ERAS Down? Discussions Forecast

Erasca Inc stock is currently priced at $2.14, with a 24-hour trading volume of 258.58K. It has seen a -0.47% decreased in the last 24 hours and a -1.38% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.12 pivot point. If it approaches the $2.20 resistance level, significant changes may occur.

Previous Close:

$2.15

Open:

$2.22

24h Volume:

258.58K

Market Cap:

$370.99M

Revenue:

Net Income/Loss:

$-125.04M

P/E Ratio:

-1.2022

EPS:

-1.78

Net Cash Flow:

$-122.99M

1W Performance:

+13.23%

1M Performance:

-1.38%

6M Performance:

-11.57%

1Y Performance:

-23.57%

1D Range:

$2.11

$2.23

52W Range:

$1.51

$3.375

Erasca Inc Stock (ERAS) Company Profile

Name

Erasca Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

858-465-6511

Address

10835 Road to the Cure, Suite 140, San Diego

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ERAS's Discussions on Twitter

Erasca Inc Stock (ERAS) Latest News

Erasca Inc Stock (ERAS) Financials Data

Erasca Inc (ERAS) Net Income 2024

ERAS net income (TTM) was -$125.04 million for the quarter ending December 31, 2023, a +48.50% increase year-over-year.

Erasca Inc (ERAS) Cash Flow 2024

ERAS recorded a free cash flow (TTM) of -$122.99 million for the quarter ending December 31, 2023, a -2.65% decrease year-over-year.

Erasca Inc (ERAS) Earnings per Share 2024

ERAS earnings per share (TTM) was -$0.82 for the quarter ending December 31, 2023, a +58.16% growth year-over-year.

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.